Skip to main content

Advertisement

SpringerLink
Log in

Comparing outcomes in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration treated with two different doses of primary intravitreal bevacizumab: results of the pan-american collaborative retina study group (PACORES) at the 12-month follow-up

  • Clinical Investigation
  • Published:
Japanese Journal of Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To compare the total number of injections and the anatomic and best-corrected visual acuity (VA) response after injecting 1.25 or 2.5 mg of bevacizumab as needed in patients with primary choroidal neovascularization secondary to age-related macular degeneration (AMD) at 12 months.

Methods

This was a retrospective, interventional, comparative multicenter study of 60 eyes treated with intravitreal bevacizumab (35 eyes, 1.25 mg; 25 eyes, 2.5 mg).

Results

The mean number of injections per eye was 3.8 in the 1.25-mg group and 3.2 in the 2.5-mg group (P = 0.2752). At 12 months, in the 1.25-mg group, 16 (46%) eyes gained ≥3 lines of Early Treatment Diabetic Retinopathy Study (ETDRS) VA and seven (20%) lost ≥3 lines of ETDRS VA. In the 2.5-mg group, 11 (44%) eyes improved by ≥3 lines, and four (16%) lost ≥3 lines (P = 1.000). At 12 months, in the 1.25-mg group, the mean central macular thickness decreased from 419 ± 201 μm at baseline to 268 ± 96 μm, compared with a decrease from 388 ± 162 to 296 ± 114 μm in the 2.5-mg group (P = 0.7896).

Conclusion

There were no statistically significant differences between the two dose groups with regard to the number of injections, anatomic and VA outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ferris FLIII, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984;102:1640–1642.

    Article  PubMed  Google Scholar 

  2. Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration. Am J Ophthalmol 2004;137:486–495.

    Article  PubMed  Google Scholar 

  3. Bressler NM, Bressler SB, Congdon NG, et al. Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol 2003;121:1621–1624.

    Article  PubMed  Google Scholar 

  4. Campochiaro PA, Soloway P, Ryan SJ, Miller JW. The pathogenesis of choroidal neovascularization in patients with age-related macular degeneration. Mol Vis 1999;5:34.

    CAS  PubMed  Google Scholar 

  5. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal antivascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002;120:338–346.

    Article  CAS  PubMed  Google Scholar 

  6. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003;22:1–29.

    Article  CAS  PubMed  Google Scholar 

  7. Husain D, Ambati B, Adamis AP, Miller JW. Mechanisms of agerelated macular degeneration. Ophthalmol Clin North Am 2002;15:87–91.

    Article  PubMed  Google Scholar 

  8. Lopez PF, Sippy BD, Lambert HM, et al. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1996;37:855–868.

    CAS  PubMed  Google Scholar 

  9. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996;37:1929–1934.

    CAS  PubMed  Google Scholar 

  10. Frank RN, Amin RH, Eliott D, et al. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol 1996;122:393–403.

    Article  CAS  PubMed  Google Scholar 

  11. Spilsbury K, Garrett KL, Shen WY, et al. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol 2000;157:135–144.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391–400.

    Article  CAS  PubMed  Google Scholar 

  13. Aggio FB, Farah ME, Silva WC, Melo GB. Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments. Graefes Arch Clin Exp Ophthalmol 2007;245:215–220.

    Article  CAS  PubMed  Google Scholar 

  14. Aisenbrey S, Ziemssen F, Volker M, et al. Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in agerelated macular degeneration. Graefes Arch Clin Exp Ophthalmol 2007;245:941–948.

    Article  CAS  PubMed  Google Scholar 

  15. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363–372 e5.

    Article  PubMed  Google Scholar 

  16. Bashshur ZF, Bazarbachi A, Schakal A, et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006;142:1–9.

    Article  CAS  PubMed  Google Scholar 

  17. Chen CY, Wong TY, Heriot WJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study. Am J Ophthalmol 2007;143:510–512.

    Article  CAS  PubMed  Google Scholar 

  18. Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci 2006;47:4569–4578.

    Article  PubMed  Google Scholar 

  19. Emerson MV, Lauer AK, Flaxel CJ, et al. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 2007;27:439–444.

    Article  PubMed  Google Scholar 

  20. Falkenstein IA, Cheng L, Morrison VL, et al. Standardized visual acuity results associated with primary versus secondary bevacizumab (Avastin) treatment for choroidal neovascularization in age-related macular degeneration. Retina 2007;27:701–706.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Giansanti F, Virgili G, Bini A, et al. Intravitreal bevacizumab therapy for choroidal neovascularization secondary to age-related macular degeneration: 6-month results of an open-label uncontrolled clinical study. Eur J Ophthalmol 2007;17:230–237.

    Article  CAS  PubMed  Google Scholar 

  22. Goff MJ, Johnson RN, McDonald HR, et al. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration. Retina 2007;27:432–438.

    Article  PubMed  Google Scholar 

  23. Lazic R, Gabric N. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2007;245:68–73.

    Article  CAS  PubMed  Google Scholar 

  24. Madhusudhana KC, Hannan SR, Williams CP, et al. Intravitreal bevacizumab (Avastin) for the treatment of choroidal neovascularization in age-related macular degeneration: results from 118 cases. Br J Ophthalmol 2007;91:1716–1717.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Pedersen R, Soliman W, Lund-Andersen H, Larsen M. Treatment of choroidal neovascularization using intravitreal bevacizumab. Acta Ophthalmol Scand 2007;85:526–533.

    Article  CAS  PubMed  Google Scholar 

  26. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular agerelated macular degeneration. Retina 2006;26:495–511.

    Article  PubMed  Google Scholar 

  27. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331–335.

    PubMed  Google Scholar 

  28. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26:383–390.

    PubMed  Google Scholar 

  29. Yoganathan P, Deramo VA, Lai JC, et al. Visual improvement following intravitreal bevacizumab (Avastin) in exudative agerelated macular degeneration. Retina 2006;26:994–998.

    Article  PubMed  Google Scholar 

  30. Gragoudas ES, Adamis AP, Cunningham ET, Jr., et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805–2816.

    Article  CAS  PubMed  Google Scholar 

  31. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432–1444.

    Article  CAS  PubMed  Google Scholar 

  32. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419–1431.

    Article  CAS  PubMed  Google Scholar 

  33. Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005;112:1035–1047.

    Article  PubMed  Google Scholar 

  34. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–2342.

    Article  CAS  PubMed  Google Scholar 

  35. Bashshur ZF, Schakal A, Hamam RN, et al. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration. Arch Ophthalmol 2007;125:1357–1361.

    Article  CAS  PubMed  Google Scholar 

  36. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008;246:81–87.

    Article  CAS  PubMed  Google Scholar 

  37. Schachat AP, Chambers WA, Liesegang TJ, Albert DA. Safe and effective. Ophthalmology 2003;110:2073–2074.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Instituto de Cirugia Ocular, San Jose, Costa Rica

    Lihteh Wu & Teodoro Evans

  2. Retina and Vitreous Service, Clinica Oftalmológica Centro Caracas, Caracas, Venezuela

    J. Fernando Arevalo & Juan Sanchez

  3. Departamento de Oftalmologia, Instituto da Visão, Universidade Federal de São Paulo, São Paulo, Brazil

    Mauricio Maia

  4. University of Puerto Rico, San Juan, Puerto Rico

    Maria H. Berrocal

  5. Apdo 144-1225 Plaza Mayor, San Jose, Costa Rica, 1225

    Lihteh Wu

Authors
  1. Lihteh Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Fernando Arevalo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mauricio Maia
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maria H. Berrocal
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Juan Sanchez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Teodoro Evans
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

the Pan-American Collaborative Retina Study Group (PACORES)

Corresponding author

Correspondence to Lihteh Wu.

Additional information

For a complete listing of participating members of PACORES see Appendix

About this article

Cite this article

Wu, L., Fernando Arevalo, J., Maia, M. et al. Comparing outcomes in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration treated with two different doses of primary intravitreal bevacizumab: results of the pan-american collaborative retina study group (PACORES) at the 12-month follow-up. Jpn J Ophthalmol 53, 125–130 (2009). https://doi.org/10.1007/s10384-008-0622-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10384-008-0622-y

Key Words

Search

Navigation